Beacon Therapeutics is a biotech company that develops ophthalmic gene therapy solutions. It offers X-linked retinitis pigmentosa (XLRP), a genetic disorder that causes vision loss due to the degeneration of light-sensitive cells in the retina, leading to blindness; Dry Age-Related Macular Degeneration (dAMD), a retinal disease that can cause central vision blurriness due to aging-related macular damage; and Cone-rod dystrophy (CRD), an inherited retinal disease that affects both cone and rod photoreceptor cells in the retina.